A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes

Marc Ciosi(University of Glasgow), Alastair Maxwell(University of Glasgow), Sarah A. Cumming(University of Glasgow), Davina J. Hensman Moss(Huntington's Disease Association), Asma M. Alshammari(University of Glasgow), Michael Flower(Huntington's Disease Association), Alexandra Dürr(Centre National de la Recherche Scientifique), Blair R. Leavitt(University of British Columbia), Raymund A.C. Roos(Leiden University Medical Center), Peter Holmans(Cardiff University), Lesley Jones(Cardiff University), Douglas R. Langbehn(University of Iowa), Seung Kwak(CHDI Foundation), Sarah J. Tabrizi(UK Dementia Research Institute), Darren G. Monckton(University of Glasgow)
EBioMedicine
October 1, 2019
Cited by 178Open Access
Full Text

Abstract

BACKGROUND: Huntington disease (HD) is caused by an unstable CAG/CAA repeat expansion encoding a toxic polyglutamine tract. Here, we tested the hypotheses that HD outcomes are impacted by somatic expansion of, and polymorphisms within, the HTT CAG/CAA glutamine-encoding repeat, and DNA repair genes. METHODS: The sequence of the glutamine-encoding repeat and the proportion of somatic CAG expansions in blood DNA from participants inheriting 40 to 50 CAG repeats within the TRACK-HD and Enroll-HD cohorts were determined using high-throughput ultra-deep-sequencing. Candidate gene polymorphisms were genotyped using kompetitive allele-specific PCR (KASP). Genotypic associations were assessed using time-to-event and regression analyses. FINDINGS: ), MLH1 (pFDR = 0·004) and MSH3 (pFDR = 0·009). We also show that HD outcomes are best predicted by the number of pure CAGs rather than total encoded-glutamines. INTERPRETATION: These data establish pure CAG length, rather than encoded-glutamine, as the key inherited determinant of downstream pathophysiology. These findings have implications for HD diagnostics, and support somatic expansion as a mechanistic link for genetic modifiers of clinical outcomes, a driver of disease, and potential therapeutic target in HD and related repeat expansion disorders. FUNDING: CHDI Foundation.


Related Papers

No related papers found

Powered by citation graph analysis